Jerry S. Wolinsky

The University of Texas Health Science Center at Houston — United States

Medicine · Health Sciences

40h-index4.2kcitations130works20.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virology and Viral Diseases(39), Multiple Sclerosis Research Studies(37), Respiratory viral infections research(15), Peripheral Neuropathies and Disorders(13), Virus-based gene therapy research(9)

Publications130 total

T16. THE ASSOCIATION BETWEEN DEPRESSION POLYGENICITY AND DISEASE ACTIVITY AND DISABILITY WORSENING IN MULTIPLE SCLEROSIS
European Neuropsychopharmacology·2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
The Lancet Neurology·2024· 55 cited
10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)
Neurology·2024· 6 cited
Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)
Multiple Sclerosis and Related Disorders·2023· 2 cited
Update on Long-Term Efficacy and Safety of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Over 5 Years from an Ongoing Phase 2 Open-Label Extension
Multiple Sclerosis and Related Disorders·2023· 2 cited
Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension (S16.008)
Neurology·2023· 3 citedOpen Access
Trigeminal neuralgia in multiple sclerosis: Association with demyelination and progression
Multiple Sclerosis and Related Disorders·2023· 15 cited
Résultats cliniques et d’imagerie par résonance magnétique de l’évobrutinib (EVO), un inhibiteur de la tyrosine kinase de Bruton (BTKi), dans le traitement de la sclérose en plaques récurrente (SEP-R) sur une période de 2,5 ans dans l’extension en ouvert
Revue Neurologique·2023
034  Updated safety analysis of ocrelizumab in multiple sclerosis
Journal of Neurology Neurosurgery & Psychiatry·2022
031  Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years
Journal of Neurology Neurosurgery & Psychiatry·2022· 1 cited
020  Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years
Journal of Neurology Neurosurgery & Psychiatry·2022
Long-Term Suppression of MRI Disease Activity and Reduction of Global/Regional Volume Loss: Results from OPERA I/II and ORATORIO Open-Label Extension (P6-4.002)
Neurology·2022
The Impact of BMI on Brain Volume and Cognitive Function in RRMS: A Secondary Analysis (P17-4.004)
Neurology·2022
Cerebellar pathology and disability worsening in relapsing‐remitting multiple sclerosis: A retrospective analysis from the CombiRx trial
European Journal of Neurology·2021· 5 citedOpen Access
Taux de poussées chez les patients atteints de SEP rémittente traités par evobrutinib, un inhibiteur de la BTK : résultats d’extension de l’étude de phase II
Revue Neurologique·2021Open Access
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
European Journal of Neurology·2021· 15 citedOpen Access
The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
Journal of Central Nervous System Disease·2021· 6 citedOpen Access
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (1147)
Neurology·2020· 2 cited
Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS (680)
Neurology·2020· 4 cited
Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
Journal of the Neurological Sciences·2019· 5 cited
page 1 of 7Next →

Frequent Co-authors

M. Neal Waxham(8), J. Richard Baringer(6), A Lovett(4), Alfred C. Server(4), David C. Merz(4), Douglas L. Arnold(3), Amit Bar‐Or(3), Gary W. Goldstein(3), Ponnada A. Narayana(3), Kenneth P. Johnson(3), Micheline McCarthy(3), Paul O’Connor(3), Jeannette J. Townsend(3), Brenda Banwell(2), Gavin Giovannoni(2), Emmanuelle Waubant(2), Judit Csejtey(2), Opendra Narayan(2), Janice E. Clements(2), B. O. Berg(2)